CHELATION TREATMENT IS MOST EFFECTIVE IF ADMINISTERED WITHIN THE FIRST 24 HOURS AFTER INTERNAL CONTAMINATION AND SHOULD BE STARTED AS SOON AS POSSIBLE.
INDIVIDUALS SHOULD DRINK PLENTY OF FLUIDS AND VOID FREQUENTLY TO PROMOTE DILUTION OF THE RADIOACTIVE CHELATE IN THE URINE AND MINIMIZE RADIATION EXPOSURE DIRECTLY TO THE BLADDER.
INITIAL DOSE:
ADULTS AND ADOLESCENTS: A SINGLE 1.0 GRAM INITIAL DOSE OF CA-DTPA ADMINISTERED INTRAVENOUSLY.
PEDIATRICS (LESS THAN 12 YEARS OF AGE): A SINGLE INITIAL DOSE OF 14 MG/KG ADMINISTERED INTRAVENOUSLY NOT TO EXCEED 1.0 GRAM.
MAINTENANCE TREATMENT:
AFTER THE INITIAL DOSE, ON THE NEXT DAY, IF ADDITIONAL CHELATION THERAPY IS INDICATED, IT IS PREFERABLE TO SWITCH TO ZN-DTPA, IF AVAILABLE DUE TO THE SAFETY CONCERNS ASSOCIATED WITH PROLONGED CA-DTPA USE. IF ZN-DTPA IS NOT AVAILABLE, TREATMENT MAY CONTINUE WITH CA-DTPA, HOWEVER MINERAL SUPPLEMENTS CONTAINING ZINC SHOULD BE GIVEN CONCOMITANTLY, AS APPROPRIATE.
ADULTS AND ADOLESCENTS: THE RECOMMENDED MAINTENANCE DOSE OF CA-DTPA IS 1.0 GRAM ONCE A DAY ADMINISTERED INTRAVENOUSLY.
PEDIATRICS (LESS THAN 12 YEARS OF AGE): THE RECOMMENDED MAINTENANCE DOSE OF CA-DTPA IS 14 MG/KG ONCE A DAY ADMINISTERED INTRAVENOUSLY. THE MAXIMUM DAILY DOSE SHOULD NOT EXCEED 1.0 GRAM PER DAY.